Our findings of different clinical outcomes by KRAS mutation subtypes and co-mutation status suggest an allele- and co-mutation-specific impact of KRAS mutations on pancreatic cancer outcomes and provide guidance in improving approaches to target KRAS in pancreatic cancer. The gene discussed is KRAS; the disease is pancreatic neoplasm.